SI-BONE is a medical device company focused on titanium implants for the sacropelvic anatomy — the region where the spine meets the pelvis. Its flagship product family, iFuse, includes triangular and threaded titanium implants used to stabilize and fuse the sacroiliac (SI) joint, a common source of chronic lower back pain. SI-BONE has expanded beyond SI joint fusion into two adjacent markets: pelvic fixation (iFuse Bedrock Granite, used as a foundational anchor in multilevel spinal fusion procedures) and pelvic trauma (iFuse TORQ TNT, designed for sacral fragility fractures). SI-BONE sells implants on a procedure-by-procedure basis to hospitals, ASCs, and office-based labs, with revenue driven by procedure volume and ASP per case. Gross margins are high, reflecting premium pricing supported by FDA breakthrough device designations and an extensive clinical evidence base. SI-BONE sells primarily through a direct U.S. sales force of ~89 territory managers, supplemented by clinical specialists and third-party sales agents who cover case logistics. The company targets two physician groups: orthopedic and neurospine surgeons, and a newer call point of interventional spine physicians performing minimally invasive procedures in office-based settings. Favorable reimbursement designations — including Transitional Pass-Through Payment for Granite and New Technology Add-On Payment for TNT — support adoption. SI-BONE's growth strategy centers on expanding into clinical adjacencies, deepening multi-procedure engagement with its existing physician base, and growing its interventionalist business.